Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

Prior treatment

• Diagnosis or suspicion of other cause for parkinsonism such as atypical parkinsonism, dystonic tremor, essential tremor, drug-induced parkinsonism.
• Known carriers of recessive PD gene mutations PRKN, PINK1 or DJ1 (based on previous medical tests / notes).
• Currently in another ongoing interventional trial or exposure to any IMP within an experimental interventional trial within 6 months prior to screening visit (exception for EJS ACT-PD participants that are being re-randomised due to treatment arm termination following lack of activity as only a 6-week wash out period is required).
• Current suicidal ideation within one year prior to the screening visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS).
• Previous brain surgery or on a waiting list for brain surgery including deep brain stimulation and / or currently taking or on a waiting list for advanced therapies for Parkinson's disease (such as any infusion therapy).
• Monotherapy with monoamine oxidase-B inhibitor (MAO-BI).
• Previous exposure to any of the currently recruiting IMPs within 6 months prior to screening visit or previous intolerance of any of the IMPs.
• Pregnant or breastfeeding or intending to become pregnant during the study or within 70 days after the final dose of study drug.
• Participants with a history of alcohol/drug abuse/dependence within the 3 years prior to screening visit.
• Participants currently taking lithium or taken within the previous 6 months.
  • Terazosin-specific exclusion criteria
• Participants currently using alpha blockers other than tamsulosin (alfuzosin, silodosin, prazosin, terazosin, and doxazosin), including natural supplements with this action (e.g. yohimbine).

Other illness

• Clinical diagnosis of dementia or MoCA \<21 at screening visit.
• Confirmed diagnosis of cancer and is requiring active management of that cancer and/or in the view of the local team, the diagnosis and/ or its treatment may compromise their ability to remain participating in the trial for 36 months or tolerate any of the active treatments.
• Participants with a known hypersensitivity or intolerance to sartans (AT1RAs)
• Participants with a history of angioedema.

Lab values

• Participant has any concurrent medical condition, abnormal laboratory tests, progressive neurological disorder or uncontrolled, clinically significant systemic disease that, in the opinion of the Investigator, could cause study participation to be detrimental to the participant (e.g., end stage renal failure, severe heart failure, unstable angina, uncontrolled hypertension or uncontrolled orthostatic hypotension, severe liver disease, uncontrolled diabetes, or severe anaemia).
• Participants with hepatobiliary disorders or abnormal liver function tests at the screening visit consisting of one of the following:
  • ALT or AST \>2x the upper limit of normal
  • Total serum bilirubin \>1.5x ULN (except for participants with Gilbert's disease, for whom the upper limit of serum bilirubin is 51.3 μmol/l or 3mg/dl)
• Participants currently taking sartans (AT1 angiotensin receptor antagonists), aliskiren, ACE inhibitors or potassium sparing diuretics.
• Participants with hyperkalaemia (serum potassium (K+) level of ≥ 5.5 mmol/l). If hyperkalaemia is identified, one re-screening will be allowed, either within 4 weeks or after identification and treatment of precipitants.
• Participants with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.

Other

• Unable or unwilling to comply with study requirements.
• Diagnosis of clinically significant depression or \>14 on PHQ-9 at screening visit.
• Participants with either of the following:
  • Sitting systolic blood pressure (SBP) less than 100 mmHg or sitting diastolic blood pressure (DBP) less than 50 mmHg, irrespective of symptoms
  • Orthostatic hypotension defined as any of the following:
  • Decrease in BP \> 20 mmHg systolic or \> 10 mmHg diastolic on supine to standing, associated with clinical symptoms
  • Decrease in BP \>30mmHg systolic and/or BP \>15 mmHg diastolic on supine to standing regardless of symptoms
  • If the lowest BP on standing is less than 100 mmHg or lowest diastolic on standing is less than 50 mmHg If, in the assessing clinician's opinion, the postural BP drop is attributable to transient/reversible factors (e.g. related to use of antihypertensives, dehydration, elevated room temperature, postprandial state), one repeated orthostatic BP assessment is allowed once those factors are addressed; additional re-screening will be allowed if the participant has their hypotension/orthostatic hypotension treated.
  • TREATMENT-SPECIFIC EXCLUSION CRITERIA
  • In addition to the core inclusion and exclusion criteria above, there are arm-specific eligibility criteria for each arm to determine to which arms a participant can be randomised:
  • Telmisartan-specific exclusion criteria
• Participants with known aortic or mitral stenosis that the investigator judges to make telmisartan use potentially unsafe.
• Participants with known renal artery stenosis.
• Participants with a known sensitivity to quinazolines e.g. alfuzosin, silodosin, prazosin, terazosin, and doxazosin, erlotinib, gefitinib, afatinib, lapatinib, and vandetanib.

• Diagnosis by neurologist, movement disorders specialist or appropriately experienced clinician of clinically established or clinically probable PD in the clinician's opinion. In the presence of any diagnostic doubt, the Movement Disorder Society diagnostic criteria will be applied.
• Diagnosed with Parkinson's disease at age 30 years or older, no upper age limit.
• Currently on Parkinson's medication (levodopa-containing preparations or dopamine agonists, used either as single agents or in combination) for at least 2 months prior to screening visit.
• Female participants who are women of child-bearing potential (WOCP) must have confirmation of a negative pregnancy test at screening visit.
• Female participants who are WOCP and male participants and their partners who are WOCP must be taking highly effective contraceptive treatment(s).
• Documented informed consent.
• Eligible for at least one of the active treatment arms (See treatment specific exclusions).
• Randomisation should ideally take place within 3 weeks of the screening visit but no later than 4 weeks after the screening visit.
• If a participant is being re-randomised into the trial, additional timing of entry requirements must also be met:
  • For participants being re-randomised after completing 36 months' follow-up and the arm was not closed due to lack of activity, a 26-week washout period from last dose of IMP must be completed before their screening visit. If the primary analysis indicates that the IMP was ineffective then this washout period can be reduced to 6 weeks.
  • For participants being re-randomised following treatment arm termination due to lack of activity, a 6-week washout period from their last dose of IMP must be completed prior to screening assessment.